M4E(R2) - Common technical document for the registration ...
2.5.4 Overview of Efficacy 2.5.5 Overview of Safety 2.5.6 Benefits and Risks Conclusions 2.5.6.1 Therapeutic Context 2.5.6.1.1 Disease or Condition 2.5.6.1.2 Current Therapies 2.5.6.2 Benefits 2.5.6.3 Risks 2.5.6.4 Benefit-Risk Assessment 2.5.6.5 Appendix 2.5.7 Literature References Detailed discussion of content of the clinical overview ...
Download M4E(R2) - Common technical document for the registration ...
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
Advertisement
Documents from same domain
Q12 Step 2b Technical and regulatory …
www.ema.europa.euICH guideline Q12 on technical and regulatory considerations for pharmaceutical product lifecycle management EMA/CHMP/ICH/804273/2017 Page 3/36
Product, Management, Lifecycle, Product lifecycle management
Guideline on good pharmacovigilance practices …
www.ema.europa.eu9 December 2013 . EMA/816292/2011 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module VII – Periodic safety update report (Rev 1)
Guidelines, Good, Practices, Guideline on good pharmacovigilance practices, Pharmacovigilance
Guideline on good pharmacovigilance practices (GVP)
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module IX (Rev 1) EMA/827661/2011 Rev 1 Page 2/25
Guideline on good pharmacovigilance practices …
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module VIII (Rev 3) EMA/813938/2011 Rev 3 Page 2/28
Guidelines, Good, Practices, Guideline on good pharmacovigilance practices, Pharmacovigilance
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/70 Document History First Codification History Date New Codification
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/75 10 Document History 11 First Codification History Date New Codification November
Guidelines, Good, Practices, Clinical, Good clinical practice e6
Guideline on good pharmacovigilance practices …
www.ema.europa.euharmful physical or psychological effects [DIR 2001/83/EC Art 1(1 6)]. 74 Adverse event (AE); synonym: Adverse experience 75 Any untoward medical occurrence in a patient or clinical- trial subject administered a medicinal product
Guidelines, Good, Practices, Guideline on good pharmacovigilance practices, Pharmacovigilance
European Medicines Agency
www.ema.europa.eu© EMEA 2006 2 SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR BIOTECHNOLOGICAL/BIOLOGICAL PRODUCTS ICH Harmonised Tripartite Guideline
Guidelines, European, Agency, Medicine, Harmonised, European medicines agency, Ich harmonised
products1/traditional herbal medicinal products
www.ema.europa.euThere is no expectation that existing herbal medicinal products on the market will be affected by this guideline, with the exception of traditional herbal medicinal products for human use that were already
Product, Medicinal, Traditional, Herbal, Products1 traditional herbal medicinal products, Products1
Q7 Q&A - good manufacturing practice for active ...
www.ema.europa.euICH guideline Q7 on good manufacturing practice for active pharmaceutical ingredients – questions and answers EMA/CHMP/ICH/468930/2015 Page 2/37
Good, Practices, Pharmaceutical, Manufacturing, Active, Ingredients, Good manufacturing practice for active, Good manufacturing practice for active pharmaceutical ingredients
Related documents
Flame Retardants Fact Sheet
www.niehs.nih.govmaking human exposure to it widespread. It has been found in human tissue, and household dust, as well as other places in the environment, including soil, water, and fish. TBBPA appears to have endocrine-disrupting properties. 10. NTP completed the first-ever two-year cancer study of this flame retardant in both mice and
Environmental Health Risk Assessment—Guidelines for ...
www1.health.gov.auEnvironmental Health Risk Assessment—Guidelines for ... ... 1
US EPA - Chemicals Evaluated for Carcinogenic Potential ...
npic.orst.eduThe following list provides an overview of pesticide chemicals evaluated ... The evidence for the human cancer potential and the extent to which a person might be exposed (how much time and to ... 1,3-Dibromo-5,5-dimethylhydantoin 77-48-5 006317 Not Likely to Be Carcinogenic To Humans. 8/28/2000
Human, Overview, Potential, Carcinogenic, Carcinogenic potential
Bloodborne Pathogens Exposure Control Plan
ehs.weill.cornell.edu6.0 Bloodborne Pathogen Exposure Control Plan Procedures 6.1 OCCUPATIONAL EXPOSURE DETERMINATION The potential for occupational exposure to bloodborne pathogens has been assessed for all WCM employees; and was made without regard to the use of personal protective equipment, as required by the regulations.
How States Serve Infants and Their Families Affected by ...
ncsacw.samhsa.govinfants and their families affected by prenatal substance exposure • Supported two regional convenings—along with the Department of Health and Human Services regions 4, 6, 7, and 9, and their respective state teams—to advance their capacity to improve the safety, permanency, recovery, and well-being of infants and their families
TOXICOLOGICAL PROFILE FOR PROPYLENE GLYCOL
www.atsdr.cdc.govPROPYLENE GLYCOL iii UPDATE STATEMENT A Technical Report for propylene glycol was released in May 1993. This edition supersedes any previously released draft …
Toxicological Profile for Perfluoroalkyls
www.atsdr.cdc.govPERFLUOROALKYLS ii . DISCLAIMER . Use of trade names is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry, the Public Health Service, or the U.S. Department of Health and Human
Human, Disease, Agency, Registry, Substance, Toxic, Agency for toxic substances and disease registry
M 4 E Common Technical Document for the Registration of ...
www.ema.europa.eu2.5.1. Product Development Rationale 2.5.2. Overview of Biopharmaceutics 2.5.3. Overview of Clinical Pharmacology 2.5.4. Overview of Efficacy 2.5.5. Overview of Safety 2.5.6. Benefits and Risks Conclusions 2.5.7. Literature References Detailed Discussion of Content of the Clinical Overview Sections 2.5.1 Product Development Rationale